Genomics in CKD: Is This the Path Forward?

Adv Chronic Kidney Dis. 2016 Mar;23(2):120-4. doi: 10.1053/j.ackd.2016.01.017.

Abstract

Recent advances in genomics and sequencing technology have led to a better understanding of genetic risk in CKD. Genetics could account in part for racial differences in treatment response for medications including antihypertensives and immunosuppressive medications due to its correlation with ancestry. However, there is still a substantial lag between generation of this knowledge and its adoption in routine clinical care. This review summarizes the recent advances in genomics and CKD, discusses potential reasons for its underutilization, and highlights potential avenues for application of genomic information to improve clinical care and outcomes in this particularly vulnerable population.

Keywords: CKD; Disparities; Genetics; Genomics; Pharmacogenomics.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Apolipoprotein L1
  • Apolipoproteins / genetics
  • Genomics*
  • Humans
  • Lipoproteins, HDL / genetics
  • Nephrology*
  • Pharmacogenetics
  • Renal Insufficiency, Chronic / ethnology
  • Renal Insufficiency, Chronic / genetics*
  • Renin-Angiotensin System / genetics
  • Translational Medical Research

Substances

  • APOL1 protein, human
  • Apolipoprotein L1
  • Apolipoproteins
  • Lipoproteins, HDL